{"brief_title": "A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients", "brief_summary": "This study will compare kidney function in kidney transplant patients following treatment with various combinations of Zenapax, CellCept, corticosteroids, and Neoral (Cyclosporine). The anticipated time on study treatment is 6-12 months, and the target sample size is 500+ individuals.", "condition": "Kidney Transplantation", "intervention_type": "Drug", "intervention_name": "mycophenolate mofetil [CellCept]", "description": "1g po bid", "arm_group_label": "3", "criteria": "Inclusion Criteria: - adult patients greater than 18 years of age - recipients of primary kidney transplant - single-organ recipients (kidney only) Exclusion Criteria: - previous treatment with Zenapax - history of malignancy (except localized skin cancer)", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00048152.xml"}